World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
46
Citations
5938
World Ranking
4652
National Ranking
50

Wenwei Tu publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Wenwei Tu sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 147 publications — 15th percentile

15% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Wenwei Tu D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Wenwei Tu sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 46 D-Index — 8th percentile

8% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Wenwei Tu is a researcher affiliated with the University of Hong Kong in China, specializing in medicine as well as immunology and microbiology. Their work primarily focuses on immunology, infectious diseases, molecular biology, obstetrics and gynecology, and epidemiology.

The scientist's main research topics include SARS-CoV-2 and COVID-19 research, immune cell function and interaction, COVID-19 clinical research studies, reproductive system and pregnancy, COVID-19 impact on reproduction, immunotherapy and immune responses, and CAR-T cell therapy research.

Wenwei Tu has contributed to multiple publication venues, frequently publishing in:

  • Frontiers in Immunology
  • Cellular and Molecular Immunology
  • Signal Transduction and Targeted Therapy
  • Nature Communications
  • American Journal of Reproductive Immunology

Several recent papers from Wenwei Tu's research include:

  • Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer, 2020, Cellular and Molecular Immunology
  • Exosomes derived from Vδ2-T cells control Epstein-Barr virus-associated tumors and induce T cell antitumor immunity, 2020, Science Translational Medicine
  • Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents, 2022, Nature Communications
  • Exosomes derived from γδ-T cells synergize with radiotherapy and preserve antitumor activities against nasopharyngeal carcinoma in immunosuppressive microenvironment, 2022, Journal for ImmunoTherapy of Cancer
  • Glucose metabolism controls human γδ T-cell-mediated tumor immunosurveillance in diabetes, 2022, Cellular and Molecular Immunology

Frequent coauthors collaborating with Wenwei Tu include:

  • YL Lau
  • Jaime S. Rosa Duque
  • Daniel Leung
  • Malik Peiris
  • Samuel M. S. Cheng

Across their career, Wenwei Tu has produced a considerable body of work within the fields of medicine and immunology with a focus on clinical and translational aspects of immune responses, infection control, vaccine immunogenicity, and tumor immunotherapy.

Best Publications

  • Cutting Edge: Decreased Accumulation and Regulatory Function of CD4+CD25high T Cells in Human STAT5b Deficiency

    Aileen C. Cohen;Kari C. Nadeau;Wenwei Tu;Vivian Hwa

  • Persistent and Selective Deficiency of CD4+ T Cell Immunity to Cytomegalovirus in Immunocompetent Young Children

    Wenwei Tu;Sharon Chen;Margaret Sharp;Corry Dekker

  • Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer.

    Yan Xu;Zheng Xiang;Mohammed Alnaggar;Mohammed Alnaggar;Léonce Kouakanou

  • Influenza Virus Directly Infects Human Natural Killer Cells and Induces Cell Apoptosis

    Huawei Mao;Wenwei Tu;Gang Qin;Helen K. W. Law

  • Phosphoantigen-Expanded Human γδ T Cells Display Potent Cytotoxicity against Monocyte-Derived Macrophages Infected with Human and Avian Influenza Viruses

    Gang Qin;Huawei Mao;Jian Zheng;Sin Fun Sia

  • Cytotoxic T Lymphocytes Established by Seasonal Human Influenza Cross-React against 2009 Pandemic H1N1 Influenza Virus

    Wenwei Tu;Huawei Mao;Jian Zheng;Yinping Liu

  • γδ-T cells: an unpolished sword in human anti-infection immunity

    Jian Zheng;Yinping Liu;Yu-Lung Lau;Wenwei Tu

  • Targeted Activation of Human Vγ9Vδ2-T Cells Controls Epstein-Barr Virus-Induced B Cell Lymphoproliferative Disease

    Zheng Xiang;Yinping Liu;Jian Zheng;Ming Liu

  • Decreased yield, phenotypic expression and function of immature monocyte-derived dendritic cells in cord blood.

    Enmei Liu;Wenwei Tu;Helen K. W. Law;Yu-Lung Lau

  • The aminobisphosphonate pamidronate controls influenza pathogenesis by expanding a γδ T cell population in humanized mice

    Wenwei Tu;Wenwei Tu;Jian Zheng;Yinping Liu;Sin Fun Sia

  • Efficient generation of human alloantigen-specific CD4+ regulatory T cells from naive precursors by CD40-activated B cells.

    Wenwei Tu;Yu-Lung Lau;Jian Zheng;Yinping Liu

  • Inhibition of Human Natural Killer Cell Activity by Influenza Virions and Hemagglutinin

    Huawei Mao;Wenwei Tu;Yinping Liu;Gang Qin

  • T-Cell Immunity to Subclinical Cytomegalovirus Infection Reduces Cardiac Allograft Disease

    Wenwei Tu;Luciano Potena;Pamela Stepick-Biek;Lanxiang Liu

  • PD-1/PD-L1 Pathway Mediates the Alleviation of Pulmonary Fibrosis by Human Mesenchymal Stem Cells in Humanized Mice

    Ke Ni;Ming Liu;Jian Zheng;Liyan Wen

  • Type 1 Responses of Human Vγ9Vδ2 T Cells to Influenza A Viruses

    Gang Qin;Yinping Liu;Jian Zheng;Iris H. Y. Ng;Iris H. Y. Ng

  • Human CD8+ regulatory T cells inhibit GVHD and preserve general immunity in humanized mice

    Wenwei Tu;Yinping Liu;Jian Zheng

  • Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents

    Unknown

  • Exosomes derived from Vδ2-T cells control Epstein-Barr virus-associated tumors and induce T cell antitumor immunity.

    Xiwei Wang;Zheng Xiang;Yinping Liu;Chunyu Huang

  • A novel H1N1 virus causes the first pandemic of the 21st century.

    J. S. Malik Peiris;Wen-wei Tu;Hui-ling Yen

  • Impaired Accumulation and Function of Memory CD4 T Cells in Human IL-12 Receptor β1 Deficiency

    Aileen M. Cleary;Wenwei Tu;Andrea Enright;Thierry Giffon

  • Human Vγ9Vδ2-T cells efficiently kill influenza virus-infected lung alveolar epithelial cells

    Hong Li;Zheng Xiang;Ting Feng;Jinrong Li

  • CD40-activated B cells are more potent than immature dendritic cells to induce and expand CD4(+) regulatory T cells.

    Jian Zheng;Yinping Liu;Yu-Lung Lau;Wenwei Tu;Wenwei Tu

  • 2001 Keystone Symposium: Decreased yield, phenotypic expression and function of immature monocyte-derived dendritic cells in cord blood

    EM Liu;WW Tu;Hkw Law;YL Lau

Frequent Co-Authors

Yu-Lung Lau
Yu-Lung Lau University of Hong Kong
David B. Lewis
David B. Lewis Stanford University
Ron G. Rosenfeld
Ron G. Rosenfeld Oregon Health & Science University
Hui-Ling Yen
Hui-Ling Yen University of Hong Kong
Joseph S. M. Peiris
Joseph S. M. Peiris University of Hong Kong
Kari C. Nadeau
Kari C. Nadeau Harvard University
Alan M. Krensky
Alan M. Krensky Northwestern University
Ann M. Arvin
Ann M. Arvin Stanford University
Shie-Liang Hsieh
Shie-Liang Hsieh Academia Sinica
Malik Peiris
Malik Peiris University of Hong Kong

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related healthcare degrees can open up diverse career pathways. Nursing programs, for example, offer practical entry points into the medical field. Many students seek lpn schools easy to get into as a manageable starting option. Licensed Practical Nurse programs provide essential foundational knowledge with flexible admission criteria.

Advancing further, aspiring nurses might consider nurse practitioner degrees. Identifying the easiest np program can help streamline the path to becoming a nurse practitioner. These programs balance comprehensive clinical training with accessibility, facilitating career growth in specialized fields.

For those focused on mental health, online Psychiatric Mental Health Nurse Practitioner (PMHNP) programs are particularly relevant. Programs with strong reputations and support systems stand out, such as the top online pmhnp programs with best clinical placement rates. These programs ensure students gain valuable hands-on experience during their studies.

Cost is a crucial factor in education decisions. Prospective students can also consider the cheapest psych np programs for quality education without excessive financial burden. Careful selection of affordable, reputable programs can make pursuing healthcare specialties more accessible to many.

Best Scientists Citing Wenwei Tu

Trending Scientists

Recently Published Articles